Common Colorectal Cancer Medications

The FDA is expected to decide on approving glofitamab in relapsed or refractory diffuse large B-cell lymphoma by July 20, 2025.

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

Results from the phase 3 ADRIATIC trial led to the approval of durvalumab in limited-stage SCLC.

Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.

Zenocutuzumab is now approved for patients with NRG1 fusion-positive NSCLC or pancreatic adenocarcinoma.

For patients with EGFR-mutated non–small cell lung cancer, sacituzumab tirumotecan was given the breakthrough drug designation by the FDA.